Gain detailed insights into the trading activity of Congress members for Healthpeak Properties on our government trades page. Stay updated on how elected officials are investing in DOC.

Healthpeak Properties - Government Trades

Healthpeak Properties

Physicians Realty Trust

Healthpeak owns a diversified healthcare portfolio of approximately 672 in-place properties spread across mainly medical office and life science assets, plus a handful of senior housing, hospital, and skilled nursing/post-acute care assets, as well.

Businessman,Hand,Arranging,Wood,Block,With,Reit.,Cube,Wooden,Block

REIT

Dividends

Trading Ideas

Real Estate

VICI

REITs are top picks for income investors, offering high yield and growth potential. Healthpeak, Realty Income, and VICI Properties are standout choices.

High-Yield REITs To Watch: Three Wall Street-Approved S&amp;P 500 Gems

Earnings

Large Cap

Mid Cap

News

Price Target

Markets

Analyst Ratings

CHWY

Interest rates determine the risk and reward perceptions of virtually all asset classes in the financial market. The benchmark for return is—and has always been—the United States ten-year treasury bond yield, so when bond yields are high, investors tend to avoid higher-risk assets like stocks, as the risk is not worth it compared to bond yields.

Lower Rates, Higher Returns: Key Stocks to Watch Now


Interest rates determine the risk and reward perceptions of virtually all asset classes in the financial market. The benchmark for return is—and has always been—the United States ten-year treasury bond

Earnings Beats

Guidance

SBAC

SBA Communications Corporation (NASDAQ: SBAC) reported second-quarter 2024 adjusted funds from operations (AFFO) per share of $3.29, beating the Zacks Consensus Estimate by a whisker. Moreover, the figure reflects a rise of 1.5% from the prior-year quarter.

SBA Communications&#39; Q2 AFFO Beat, Revenues Fall Y/Y

AGNC

Wall Street watches a company&#39;s quarterly report closely to understand as much as possible about its recent performance and what to expect going forward. Of course, one figure often stands out among the rest: earnings.

These 2 Finance Stocks Could Beat Earnings: Why They Should Be on Your Radar

Miniature,Wooden,Houses,And,A,Green,Arrow,Down.,The,Concept

7 REITs Receive Analyst Upgrades In The First Week Of May

ALEX

REXR

3 REITs That Just Raised 2024 Full-Year Guidance

Buy,Or,Sell,Buttons,Concept.,Close,Up,Computer,Screen,View

AMZN

Analysts Just Upgraded These 4 REITs

Short Ideas

Small Cap

Pre-Market Outlook

CHCI

As of April 4, 2024, three stocks in the real estate sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 3 Real Estate Stocks That Are Ticking Portfolio Bombs

Reit,Real,Estate,Investment,Trust,Symbol.,Concept,Words,Reit,Real

PEAK

SITC

STAG

2024&#39;s Rough Start: More Than A Half Dozen REITs Get Downgrades

Healthpeak Properties Inc

Dock

BEYOND MED TECHS INC by BEYOND MED TECHNOLOGIES INC.

Beyond Medical Technologies Inc

Dr. Martens PLC

DigitalOcean Holdings Inc

CloudMD Software & Services Inc Ordinary Shares

Doximity Inc

FT Vest U.S. Equity Deep Buffer ETF - October

DocuSign Inc

<p>Wells Fargo  analyst Connor Siversky   maintains Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) with a Equal-Weight and lowers the price target from $23 to $22.</p>


Wells Fargo Maintains Equal-Weight on Healthpeak Properties, Lowers Price Target to $22

<p>Across the recent three months, 7 analysts have shared their insights on Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $25.14, a high estimate of $28.00, and a low estimate of $23.00. This upward trend is evident, with the current average reflecting a 7.3% increase from the previous average price target of $23.43.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1733410811_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The standing of Healthpeak Properties among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vikram Malhotra</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Amanda Sweitzer</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Omotayo Okusanya</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$28.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Connor Siversky</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$23.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>James Kammert</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$24.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Healthpeak Properties. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Healthpeak Properties compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Capture valuable insights into Healthpeak Properties's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DOC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Healthpeak Properties analyst ratings.</strong></a></p>
<h2>All You Need to Know About Healthpeak Properties</h2>
<p>Healthpeak owns a diversified healthcare portfolio of approximately 672 in-place properties spread across mainly medical office and life science assets, plus a handful of senior housing, hospital, and skilled nursing/post-acute care assets, as well.</p>
<h3>Healthpeak Properties: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Revenue Growth:</strong> Healthpeak Properties's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>24.54%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> Healthpeak Properties's net margin is impressive, surpassing industry averages. With a net margin of <strong>12.49%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Healthpeak Properties's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>0.99%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>0.43%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.04</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Expert Ratings For Healthpeak Properties

<p>Mizuho  analyst Vikram Malhotra   maintains Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) with a Outperform and lowers the price target from $25 to $24.</p>


Mizuho Maintains Outperform on Healthpeak Properties, Lowers Price Target to $24

<p>In the current session, the stock is trading at $22.35, after a <strong>0.49%</strong> spike. Over the past month, <strong>Healthpeak Properties Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>)</strong> stock increased by <strong>2.58%</strong>, and in the past year, by <strong>20.41%</strong>. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.</p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2024/1732885258_0.png" alt="Past Year Chart" /></p>

<h3>Healthpeak Properties P/E Ratio Analysis in Relation to Industry Peers</h3>
<p>The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. </p>
<p>Compared to the aggregate P/E ratio of <strong>44.45</strong> in the Helath Care REITs industry, Healthpeak Properties Inc. has a higher P/E ratio of <strong>45.39</strong>. Shareholders might be inclined to think that Healthpeak Properties Inc. might perform better than its industry group. It's also possible that the stock is overvalued. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2024/1732885258_1.png" alt="Guage" /></p>

<p>In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes. </p>


Intraday Update

Price Over Earnings Overview: Healthpeak Properties

<p>For income-focused investors, <a href="https://www.benzinga.com/real-estate/reit">real estate investment trusts (REITs)</a> are a goldmine, offering steady dividends backed by tangible assets. </p>
<p>Our search for top REITs focused on large-cap stocks from the S&amp;P 500 index with a dividend yield exceeding 5% and Wall Street analysts rating them a "Buy" or higher. This rigorous filter led us to three standout picks that combine high yield with growth potential. From healthcare facilities to retail and casinos, these REITs provide both robust income and diversified exposure.</p>
<h2 class="wp-block-heading">1. Healthpeak Properties Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>): A Prescription For Income</h2>
<p><strong>Dividend Yield:</strong> 5.40%<br /><strong>Market Cap:</strong> $15.81 billion<br /><strong>Sector:</strong> Healthcare Facilities</p>
<p>Healthpeak Properties is a healthcare-focused REIT with a flair for stability and growth. Offering a 5.40% dividend yield, DOC has seen a stellar 30.67% performance over the past year and 12.32% year-to-date gains. Its price-to-free-cash-flow (P/FCF) ratio of 18.41 signals a fair valuation, making it an attractive choice for yield-seeking investors.</p>
<p>With the healthcare sector&#8217;s resilience, Healthpeak benefits from long-term demographic trends like aging populations, positioning itself as a dependable dividend payer in a defensive industry.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/real-estate/reit/24/11/42068836/crowdstreets-new-ceo-john-imbriglia-charts-a-bold-path-for-commercial-real-estate-investors">CrowdStreet&#8217;s New CEO John Imbriglia Charts a Bold Path for Commercial Real Estate Investors</a></strong></p>
<h2 class="wp-block-heading">2. Realty Income Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/O#NYSE">O</a>): The Monthly Dividend Machine</h2>
<p><strong>Dividend Yield:</strong> 5.37%<br /><strong>Market Cap:</strong> $51.55 billion<br /><strong>Sector:</strong> Retail</p>
<p>Nicknamed "The Monthly Dividend Company," Realty Income is a household name in income investing. Offering a 5.37% yield, O maintains a strong foothold in retail real estate, with a portfolio diversified across industries and tenants. Despite modest performance year-to-date (1.57%), its P/FCF of 15.84 underscores solid fundamentals.</p>
<p>Realty Income's consistent payouts and reputation for reliable income make it a cornerstone for dividend-focused portfolios. Whether the market&#8217;s hot or cold, this REIT remains a fan favorite for its unwavering commitment to shareholder returns.</p>
<h2 class="wp-block-heading"><strong>3. VICI Properties Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VICI#NYSE">VICI</a>): A Jackpot For Investors</strong></h2>
<p><strong>Dividend Yield:</strong> 5.20%<br /><strong>Market Cap:</strong> $34.60 billion<br /><strong>Sector:</strong> Diversified</p>
<p>VICI Properties owns an enviable portfolio of casino and gaming assets, including Las Vegas landmarks. Its 5.20% dividend yield is paired with a P/FCF of 15.01, making it the most attractively valued among our picks. Over the past six months, VICI has outperformed with a 16.18% gain, outpacing broader market indices.</p>
<p>As the gaming industry recovers post-pandemic, VICI is well-positioned to capture growth while rewarding investors with consistent income. With its diversified exposure and high yield, this REIT is a safe bet for any portfolio.</p>
<p>These REITs—Healthpeak, Realty Income, and VICI Properties—combine strong dividend yields with promising growth, backed by Wall Street's confidence. </p>
<p>Whether you're looking for healthcare stability, retail reliability, or a gamble on casinos, these large-cap REITs deliver income with the potential for capital appreciation. For investors, the choice is clear: when it comes to dividends, these are the real estate crown jewels.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/real-estate/reit/24/11/42044923/goldman-sachs-turns-bearish-on-redfin-affordability-could-weigh-on-a-housing-recovery">Goldman Sachs Turns Bearish On Redfin: &#8216;Affordability Could Weigh On A Housing Recovery&#8217;</a></strong></li>
</ul>


High-Yield REITs To Watch: Three Wall Street-Approved S&P 500 Gems

Healthpeak Properties Raises FY24 AFFO From $1.56-$1.58 To $1.57-$1.59

<p>RBC Capital  analyst Michael Carroll   maintains Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) with a Outperform and raises the price target from $25 to $26.</p>


RBC Capital Maintains Outperform on Healthpeak Properties, Raises Price Target to $26

<p>Baird  analyst Amanda Sweitzer   maintains Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) with a Outperform and raises the price target from $24 to $25.</p>


Baird Maintains Outperform on Healthpeak Properties, Raises Price Target to $25

Healthpeak Properties Revises FY24 FFO As Adjusted Per Share From $1.77 – $1.81 To $1.79 – $1.81; AFFO Per Share From $1.54 – $1.58 To $1.56 – $1.58

Healthpeak Properties Q3 2024 AFFO Per Share $0.41, Up From $0.40 Prior Year; Total Revenues $700.4M, Up From $556.24M Last Year

<p>Throughout the last three months, 8 analysts have evaluated Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Healthpeak Properties and provided 12-month price targets. The average target is $24.75, accompanied by a high estimate of $28.00 and a low estimate of $22.00. Observing a 11.24% increase, the current average has risen from the previous average price target of $22.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729540821_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of Healthpeak Properties among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omotayo Okusanya</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$28.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Connor Siversky</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$23.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>James Kammert</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$24.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>James Kammert</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Michael Bilerman</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Healthpeak Properties. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Healthpeak Properties compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Healthpeak Properties's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Healthpeak Properties's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DOC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Healthpeak Properties analyst ratings.</strong></a></p>
<h2>Get to Know Healthpeak Properties Better</h2>
<p>Healthpeak owns a diversified healthcare portfolio of approximately 748 in-place properties spread across mainly medical office and life science assets, plus a handful of senior housing, hospital, and skilled nursing/post-acute care assets, as well.</p>
<h3>A Deep Dive into Healthpeak Properties's Financials</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Healthpeak Properties showcased positive performance, achieving a revenue growth rate of <strong>27.31%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> Healthpeak Properties's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>21.21%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Healthpeak Properties's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>1.65%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Healthpeak Properties's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.72%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Healthpeak Properties's debt-to-equity ratio is below the industry average. With a ratio of <b>1.02</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Where Healthpeak Properties Stands With Analysts

<p>In the last three months, 8 analysts have published ratings on Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $24.75, a high estimate of $28.00, and a low estimate of $22.00. Observing a 11.24% increase, the current average has risen from the previous average price target of $22.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729526442_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>A clear picture of Healthpeak Properties's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omotayo Okusanya</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$28.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Connor Siversky</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$23.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>James Kammert</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$24.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>James Kammert</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Michael Bilerman</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Healthpeak Properties. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Healthpeak Properties compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Healthpeak Properties's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Healthpeak Properties's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DOC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Healthpeak Properties analyst ratings.</strong></a></p>
<h2>All You Need to Know About Healthpeak Properties</h2>
<p>Healthpeak owns a diversified healthcare portfolio of approximately 748 in-place properties spread across mainly medical office and life science assets, plus a handful of senior housing, hospital, and skilled nursing/post-acute care assets, as well.</p>
<h3>Unraveling the Financial Story of Healthpeak Properties</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Healthpeak Properties showcased positive performance, achieving a revenue growth rate of <strong>27.31%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> Healthpeak Properties's net margin excels beyond industry benchmarks, reaching <strong>21.21%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Healthpeak Properties's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>1.65%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Healthpeak Properties's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>0.72%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.02</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


The Analyst Verdict: Healthpeak Properties In The Eyes Of 8 Experts

<p>Deutsche Bank  analyst Omotayo Okusanya   upgrades Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) from Hold to Buy and raises the price target from $20 to $28.</p>


Upgrades

Deutsche Bank Upgrades Healthpeak Properties to Buy, Raises Price Target to $28

<p>In the preceding three months, 6 analysts have released ratings for Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $24.5, a high estimate of $26.00, and a low estimate of $22.00. This current average has increased by 8.07% from the previous average price target of $22.67. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726502450_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The standing of Healthpeak Properties among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Kammert</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$24.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>James Kammert</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Michael Bilerman</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Healthpeak Properties. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Healthpeak Properties compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Healthpeak Properties's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Healthpeak Properties's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DOC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Healthpeak Properties analyst ratings.</strong></a></p>
<h2>Get to Know Healthpeak Properties Better</h2>
<p>Healthpeak owns a diversified healthcare portfolio of approximately 748 in-place properties spread across mainly medical office and life science assets, plus a handful of senior housing, hospital, and skilled nursing/post-acute care assets, as well.</p>
<h3>Healthpeak Properties: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Healthpeak Properties's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>27.31%</strong> as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Healthpeak Properties's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>21.21%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Healthpeak Properties's ROE excels beyond industry benchmarks, reaching <strong>1.65%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Healthpeak Properties's ROA excels beyond industry benchmarks, reaching <strong>0.72%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Healthpeak Properties's debt-to-equity ratio is below the industry average at <strong>1.02</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings For Healthpeak Properties

<p>Evercore ISI Group  analyst James Kammert   maintains Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) with a Outperform and raises the price target from $25 to $26.</p>


Evercore ISI Group Maintains Outperform on Healthpeak Properties, Raises Price Target to $26

<p>Scotiabank  analyst Nicholas Yulico   maintains Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) with a Sector Outperform and raises the price target from $23 to $24.</p>


Scotiabank Maintains Sector Outperform on Healthpeak Properties, Raises Price Target to $24

<p><strong>Healthpeak Properties's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) short percent of float has risen 36.3% since its last report. The company recently reported that it has <strong>11.00 million shares sold short</strong>, which is 1.99% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.61 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Healthpeak Properties Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1725542116_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Healthpeak Properties has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Healthpeak Properties's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Healthpeak Properties's peer group average for short interest as a percentage of float is 6.65%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Looking Into Healthpeak Properties's Recent Short Interest

<p>In the latest quarter, 4 analysts provided ratings for Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $24.25, along with a high estimate of $25.00 and a low estimate of $22.00. Marking an increase of 10.23%, the current average surpasses the previous average price target of $22.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1724864475_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>A clear picture of Healthpeak Properties's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Kammert</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Michael Bilerman</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Healthpeak Properties. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Healthpeak Properties compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Healthpeak Properties's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Healthpeak Properties's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DOC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Healthpeak Properties analyst ratings.</strong></a></p>
<h2>About Healthpeak Properties</h2>
<p>Healthpeak owns a diversified healthcare portfolio of approximately 748 in-place properties spread across mainly medical office and life science assets, plus a handful of senior housing, hospital, and skilled nursing/post-acute care assets, as well.</p>
<h3>Healthpeak Properties's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Healthpeak Properties's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>27.31%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> Healthpeak Properties's net margin is impressive, surpassing industry averages. With a net margin of <strong>21.21%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Healthpeak Properties's ROE excels beyond industry benchmarks, reaching <strong>1.65%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Healthpeak Properties's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.72%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>1.02</strong>, Healthpeak Properties adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Scoreboard: 4 Ratings For Healthpeak Properties

<p>Evercore ISI Group  analyst James Kammert   maintains Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) with a Outperform and raises the price target from $24 to $25.</p>


Evercore ISI Group Maintains Outperform on Healthpeak Properties, Raises Price Target to $25

<p>Citigroup  analyst Michael Bilerman   maintains Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) with a Neutral and raises the price target from $20 to $22.</p>



Chris JacobsHouse (R-NY)	$1K - $15K	stock	Purchase	Jan 20, 2023	Dec 12, 2022	House
Chris JacobsHouse (R-NY)	$1K - $15K	stock	Sale	Dec 12, 2022	Nov 08, 2022	House
Chris JacobsHouse (R-NY)	$1K - $15K	stock	Sale	Sep 09, 2022	Jul 18, 2022	House
Chris JacobsHouse (R-NY)	$15K - $50K	stock	Purchase	Jul 28, 2022	Jun 21, 2022	House

Government Trades

Healthpeak Properties Inc

top performing DOC trades

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga